

Orforglipron / Foundayo 12mg

Peptide • Research Use Only

Report ID	PHX-B1014-26	Test Date	27 March 2026
Product	Orforglipron / Foundayo 12mg	Laboratory	Puralytix (Independent Third-Party)
Category	Peptide	Test Method	HPLC-UV / LC-MS; ICP-MS (heavy metals)
Sample Form	Oral solid (tablet / capsule)	Label Claim (total)	12mg
Quantified (total)	12.2mg	HPLC Purity	99.4 %

COMPOUND ANALYSIS

Active compound	Label claim	Quantified	Result
Orforglipron	12mg	12.2mg	Pass

HEAVY METAL SCREEN (ICP-MS)

Lead (Pb)	Mercury (Hg)	Arsenic (As)	Cadmium (Cd)
ND (≤ 0.5 ppm)	ND (≤ 0.1 ppm)	ND (≤ 0.5 ppm)	ND (≤ 0.25 ppm)

ND = not detected at or above the stated method reporting limit (ppm).

RESULT

PASS — HPLC Purity 99.4% · Heavy metals: not detected

Verify this certificate

Report ID: **PHX-B1014-26**

Verification Key: **23DB-4667**

puralytix.com/report-verification

Enter the Report ID and Verification Key on the page above, or scan the QR code, to confirm this report is genuine.



Scan to verify

Puralytix provides independent analytical testing and informational reports only. This certificate relates solely to the sample identified above and the test methods stated. Results are subject to the inherent limitations and detection thresholds of the methods used. Puralytix does not provide medical, dosing, sourcing, legal or consumption advice, and a result does not imply that any substance is safe, approved, lawful or suitable for human use. Research use only. Clients are responsible for complying with the laws of their own jurisdiction.

Puralytix — 71 Vazha-Pshavela Avenue, Block 2, Saburtalo District, 0186 Tbilisi, Georgia